LQDA Stock Analysis: Liquidia Technologies | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 6.905m USD | 12M Return: 391.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 151M
Qual. Beats: 0
Rev. Trend: 72.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 7.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Liquidia Corporation (NASDAQ: LQDA) is a U.S.-based biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina. The company focuses on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases, with a particular emphasis on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead product candidate, YUTREPIA, is an inhaled dry-powder formulation of treprostinil targeting both PAH and PH-ILD. The company also distributes Remodulin, a continuously infused treprostinil injection, and is advancing L606, an inhaled liposomal treprostinil formulation currently in Phase III clinical trials for the same indications.
In addition to its therapeutics business, Liquidia operates a proprietary particle engineering platform called PRINT, which enables precise control over the size, geometry, and chemical composition of drug particles. This technology underpins the companys inhaled delivery approach and is also licensed to third parties, including partnerships with GlaxoSmithKline, Alcon, Vectura, the University of North Carolina at Chapel Hill, and Pharmosa Biopharm. The company has a promotion agreement with Sandoz supporting the commercialization of its treprostinil-based portfolio.
Liquidia trades as a mid-cap stock in the Health Care sector (GICS Sub-Industry: Pharmaceuticals) and went public in July 2018. Its business model combines specialty drug development for rare diseases-where treprostinil, a prostacyclin analog, is a standard-of-care therapy-with a technology licensing component, giving it multiple potential revenue streams across both product sales and platform partnerships.
- YUTREPIA FDA approval and commercial launch for PAH
- United Therapeutics patent dispute ruling impacts generic Tyvaso entry
- L606 phase III results for inhaled treprostinil formulation
| Net Income: 22.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 57.47 > 1.0 |
| NWC/Revenue: 63.64% < 20% (prev 825.0%; Δ -761.4% < -1%) |
| CFO/TA 0.12 > 3% & CFO 48.0m > Net Income 22.3m |
| Net Debt (-31.0m) to EBITDA (53.8m): -0.58 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (101.1m) vs 12m ago 18.71% < -2% |
| Gross Margin: 91.78% > 18% (prev 58.08%; Δ 33.70% > 0.5%) |
| Asset Turnover: 91.60% > 50% (prev 6.22%; Δ 85.38% > 0%) |
| Interest Coverage Ratio: 2.01 > 6 (EBIT TTM 52.2m / Interest Expense TTM 26.0m) |
| A: 0.46 (Total Current Assets 333.1m - Total Current Liabilities 149.7m) / Total Assets 401.5m |
| B: -1.43 (Retained Earnings -573.5m / Total Assets 401.5m) |
| C: 0.17 (EBIT TTM 52.2m / Avg Total Assets 314.5m) |
| D: 0.37 (Book Value of Equity 108.6m / Total Liabilities 293.0m) |
| Altman-Z'' = -0.16 = B |
| DSRI: 2.92 (Receivables 74.2m/1.25m, Revenue 288.1m/14.1m) |
| GMI: 0.63 (GM 58.08% / 91.78%) |
| AQI: 0.65 (AQ_t 0.11 / AQ_t-1 0.17) |
| SGI: 20.37 (Revenue 288.1m / 14.1m) |
| TATA: -0.06 (NI 22.3m - CFO 48.0m) / TA 401.5m) |
| Beneish M = 11.89 (Cap -4..+1) = D |
As of July 14, 2026, the stock is trading at USD 71.21 with a total of 2,168,408 shares traded. Over the past week, the price has changed by -10.10%, over one month by -0.82%, over three months by +83.29% and over the past year by +391.78%.
Current recommended Stop Loss: 66.50 (which is 6.6% or 1.2 ATR below the current price).
Liquidia Technologies has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy LQDA.
- StrongBuy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 74.3 | 4.3% |
P/E Trailing = 485.3125
P/E Forward = 39.2157
P/S = 23.9712
P/B = 66.709
Revenue TTM = 288.1m USD
EBIT TTM = 52.2m USD
EBITDA TTM = 53.8m USD
Long Term Debt = 127.6m USD (from longTermDebt, last quarter)
Short Term Debt = 51.0m USD (from shortTermDebt, last quarter)
Debt = 191.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.96m
Net Debt = -31.0m USD (calculated: Debt 191.8m - CCE 222.8m)
Enterprise Value = 6.87b USD (6.91b + Debt 191.8m - CCE 222.8m)
Interest Coverage Ratio = 2.01 (Ebit TTM 52.2m / Interest Expense TTM 26.0m)
EV/FCF = 167.1x (Enterprise Value 6.87b / FCF TTM 41.1m)
FCF Yield = 0.60% (FCF TTM 41.1m / Enterprise Value 6.87b)
FCF Margin = 14.28% (FCF TTM 41.1m / Revenue TTM 288.1m)
Net Margin = 7.74% (Net Income TTM 22.3m / Revenue TTM 288.1m)
Gross Margin = 91.78% ((Revenue TTM 288.1m - Cost of Revenue TTM 23.7m) / Revenue TTM)
Gross Margin QoQ = 90.86% (prev 92.33%)
Tobins Q-Ratio = 17.12 (Enterprise Value 6.87b / Total Assets 401.5m)
Interest Expense / Debt = 13.55% (Interest Expense 26.0m / Debt 191.8m)
Taxrate = 6.90% (3.92m / 56.8m)
NOPAT = 48.6m (EBIT 52.2m * (1 - 6.90%))
Current Ratio = 2.22 (Total Current Assets 333.1m / Total Current Liabilities 149.7m)
Debt / Equity = 1.77 (Debt 191.8m / totalStockholderEquity, last quarter 108.6m)
Debt / EBITDA = -0.58 (Net Debt -31.0m / EBITDA 53.8m)
Debt / FCF = -0.75 (Net Debt -31.0m / FCF TTM 41.1m)
Total Stockholder Equity = 47.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 22.3m / Total Assets 401.5m)
RoE = 46.82% (Net Income TTM 22.3m / Total Stockholder Equity 47.6m)
RoCE = 29.79% (EBIT 52.2m / Capital Employed (Equity 47.6m + L.T.Debt 127.6m))
RoIC = 16.86% (NOPAT 48.6m / Invested Capital 288.4m)
WACC = 9.60% (E(6.91b)/V(7.10b) * Re(9.52%) + D(191.8m)/V(7.10b) * Rd(13.55%) * (1-Tc(0.07)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.69 | Cagr: 21.64%
[DCF] Terminal Value 71.16% ; FCFF base≈41.1m ; Y1≈41.3m ; Y5≈43.8m
[DCF] Fair Price = 6.66 (EV 561.0m - Net Debt -31.0m = Equity 592.1m / Shares 88.9m; r=9.60% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.69 | # QB: 0
Revenue Correlation: 72.84 | Revenue CAGR: 132.6% | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.84 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.97 | Chg30d=+0.00% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=3.48 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+535.0% | GrowthRev=+358.0%
EPS next Year (2027-12-31): EPS=5.57 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+60.1% | GrowthRev=+63.3%
[Analyst] Revisions Ratio: +0% (up=0, down=0)